Atenção: Todas as denúncias são sigilosas e sua identidade será preservada.
Os campos nome e e-mail são de preenchimento opcional
Metadados | Descrição | Idioma |
---|---|---|
Autor(es): dc.contributor | HospitalClinic–Universitat de Barcelona | - |
Autor(es): dc.contributor | University of Zaragoza | - |
Autor(es): dc.contributor | Institute of Molecular Biology of Barcelona (IBMB–CSIC) | - |
Autor(es): dc.contributor | Universidade Estadual Paulista (Unesp) | - |
Autor(es): dc.contributor | Universitat Ramon Llull | - |
Autor(es): dc.contributor | Institució Catalana de Recerca i Estudis Avançats | - |
Autor(es): dc.contributor | School of Dentistry University of Copenhagen | - |
Autor(es): dc.contributor | Fundación ARAID | - |
Autor(es): dc.creator | Chi, Jordi | - |
Autor(es): dc.creator | Cova, Marta | - |
Autor(es): dc.creator | De Las Rivas, Matilde | - |
Autor(es): dc.creator | Medina, Ana | - |
Autor(es): dc.creator | Junqueira Borges, Rafael [UNESP] | - |
Autor(es): dc.creator | Leivar, Pablo | - |
Autor(es): dc.creator | Planas, Antoni | - |
Autor(es): dc.creator | Usón, Isabel | - |
Autor(es): dc.creator | Hurtado-Guerrero, Ramón | - |
Autor(es): dc.creator | Izquierdo, Luis | - |
Data de aceite: dc.date.accessioned | 2022-02-22T00:44:12Z | - |
Data de disponibilização: dc.date.available | 2022-02-22T00:44:12Z | - |
Data de envio: dc.date.issued | 2021-06-25 | - |
Data de envio: dc.date.issued | 2021-06-25 | - |
Data de envio: dc.date.issued | 2020-09-01 | - |
Fonte completa do material: dc.identifier | http://dx.doi.org/10.1128/mBio.02045-20 | - |
Fonte completa do material: dc.identifier | http://hdl.handle.net/11449/205390 | - |
Fonte: dc.identifier.uri | http://educapes.capes.gov.br/handle/11449/205390 | - |
Descrição: dc.description | UDP-N-acetylglucosamine (UDP-GlcNAc), the main product of the hexosamine biosynthetic pathway, is an important metabolite in protozoan parasites since its sugar moiety is incorporated into glycosylphosphatidylinositol (GPI) glycolipids and Nand O-linked glycans. Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate Nacetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s. By using conditional genetic engineering, we demonstrate the requirement of GNA1 for the generation of a pool of UDP-GlcNAc and for the development of intraerythrocytic asexual Plasmodium falciparum parasites. Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1. The indepth analysis of the crystal shows the presence of specific residues relevant for GNA1 enzymatic activity that are further investigated by the creation of site-specific mutants. The experiments reveal distinct features in apicomplexan GNA1 enzymes that could be exploitable for the generation of selective inhibitors against these parasites, by targeting the hexosamine pathway. This work underscores the potential of apicomplexan GNA1 as a drug target against malaria. IMPORTANCE Apicomplexan parasites cause a major burden on global health and economy. The absence of treatments, the emergence of resistances against available therapies, and the parasite’s ability to manipulate host cells and evade immune systems highlight the urgent need to characterize new drug targets to treat infections caused by these parasites. We demonstrate that glucosamine-6-phosphate N-acetyltransferase (GNA1), required for the biosynthesis of UDP-N-acetylglucosamine (UDP-GlcNAc), is essential for P. falciparum asexual blood stage development and that the disruption of the gene encoding this enzyme quickly causes the death of the parasite within a life cycle. The high-resolution crystal structure of the GNA1 ortholog from the apicomplexan parasite C. parvum, used here as a surrogate, highlights significant differences from human GNA1. These divergences can be exploited for the design of specific inhibitors against the malaria parasite. | - |
Descrição: dc.description | ISGlobal HospitalClinic–Universitat de Barcelona | - |
Descrição: dc.description | Institute of Biocomputation and Physics of Complex Systems (BIFI) University of Zaragoza | - |
Descrição: dc.description | Crystallographic Methods Institute of Molecular Biology of Barcelona (IBMB–CSIC) | - |
Descrição: dc.description | Departamento de Física e Biofísica Instituto de Biociências Universidade Estadual Paulista (UNESP) | - |
Descrição: dc.description | Laboratory of Biochemistry Institut Químic de Sarrià Universitat Ramon Llull | - |
Descrição: dc.description | ICREA Institució Catalana de Recerca i Estudis Avançats | - |
Descrição: dc.description | Copenhagen Center for Glycomics Department of Cellular and Molecular Medicine School of Dentistry University of Copenhagen | - |
Descrição: dc.description | Laboratorio de Microscopías Avanzada (LMA) University of Zaragoza | - |
Descrição: dc.description | Fundación ARAID | - |
Descrição: dc.description | Departamento de Física e Biofísica Instituto de Biociências Universidade Estadual Paulista (UNESP) | - |
Formato: dc.format | 1-15 | - |
Idioma: dc.language | en | - |
Relação: dc.relation | mBio | - |
???dc.source???: dc.source | Scopus | - |
Palavras-chave: dc.subject | Aminosugar pathway | - |
Palavras-chave: dc.subject | Apicomplexan parasites | - |
Palavras-chave: dc.subject | Malaria | - |
Palavras-chave: dc.subject | Metabolism | - |
Palavras-chave: dc.subject | Plasmodium falciparum | - |
Palavras-chave: dc.subject | UDP-N-acetylglucosamine | - |
Título: dc.title | Plasmodium falciparum apicomplexan-specific glucosamine-6-phosphate n-acetyltransferase is key for amino sugar metabolism and asexual blood stage development | - |
Tipo de arquivo: dc.type | livro digital | - |
Aparece nas coleções: | Repositório Institucional - Unesp |
O Portal eduCAPES é oferecido ao usuário, condicionado à aceitação dos termos, condições e avisos contidos aqui e sem modificações. A CAPES poderá modificar o conteúdo ou formato deste site ou acabar com a sua operação ou suas ferramentas a seu critério único e sem aviso prévio. Ao acessar este portal, você, usuário pessoa física ou jurídica, se declara compreender e aceitar as condições aqui estabelecidas, da seguinte forma: